Speaking Engagements
Drug Delivery Partnership Conference
Orlando, FL
January 27, 2009
CED Biotech Conference
Raleigh, NC
February 22-23, 2010
IN3 WEST
Las Vegas
March 3, 2010
2010 BIO International Convention
Chicago, IL
Will participate on a panel entitled “Accessing Capital through Risk-Sharing Models between Early-Stage Companies and Contract Research Organizations"
May 3-5, 2010
In the News
Pappas Picks Likely Heir
News and Observer
September 29, 2009
Arthur M. Pappas Elected as Biotechnology Center Board Chairman
North Carolina Biotechnology Center Press Release
September 28, 2008
Art Pappas
Managing Partner
Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He has assembled a team of investment, biotechnology and medical experts who manage over $350 million and oversee investments in more than 40 portfolio companies. Prior to founding Pappas Ventures in 1994, Art held CEO and other senior level leadership positions at several multinational pharmaceutical companies. He was an executive member of the board of directors of Glaxo Holdings plc, for which he was the chief executive responsible for international operations including research, development and manufacturing. Art previously was Vice President of Commercial Operations for Abbott International Ltd., and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. Among the companies for which he currently serves as a director are: Afferent Pharmaceuticals, CardioDx, CeNeRx BioPharma, Genstruct, LEAD Therapeutics and TyRx Pharma. He was the founding CEO and is currently the chairman of CoLucid Pharmaceuticals.
Some of the firm’s representative investments include Cerexa Pharmaceuticals (acquired by Forest Laboratories); Syntonix Pharmaceuticals (acquired by Biogen Idec); Peninsula Pharmaceuticals (acquired by Johnson & Johnson); Panacos Pharmaceuticals; NuVasive (Nasdaq: NUVA); Gene Logic; Nuvelo (Nasdaq: NUVO; previously Variagenics); and Arena Pharmaceuticals (Nasdaq: ARNA).
Art is chairman of the North Carolina Biotechnology Center’s Board of Directors and is a member of the National Venture Capital Association (NVCA) Medical Industry Group Advisory Board. He previously served on the boards of AtheroGenics (Nasdaq: AGIX), Embrex (Nasdaq: EMBX), Quintiles Transnational (Nasdaq: QTRN) and Valentis (Nasdaq: VLTS). Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and the Special Forces.
Education
Ohio State University (BS in Biology)
Xavier University (MBA in Finance)
